Charakterystyka oligodeoksynukleotydow zawierajacych motywy CpG, ich wplyw na komorki ukladu odpornosciowego oraz mozliwosci wykorzystania w medycynie i weterynarii

• Autorzy: Chrzastek K , Wieliczko A.

Warianty tytułu

EN

Characteristics of oligodeoxynucleotides containing CpG motifs: their influence on immune system cells and the possibilities of their application in medicine and veterinary medicine

• Języki publikacji: PL

Abstrakty

EN

DNA Bacterial genomes contain many more unmethylated CpG (cytosine-phosphodiester-guanine) dinucleotides than those of vertebrates. This difference in the genome structure allows the innate immune system of vertebrates to distinguish bacterial DNA from self-DNA. Synthetic oligodeoxynucleotides that contain CpG motifs (CpG ODNs) can mimic bacterial DNA and consequently induce various types and levels of immune responses. Synthetic ODNs CpG stimulates the innate immune system, activates non-specific anti-microbial defense systems, and sensitizes antigen-presenting cells to mount both antibody and cell- -mediated immunity against specific antigens. A better understanding of CpG recognition at the molecular level is fundamental to subsequent immunological response which would allow the optimization and application of CpG motifs as therapeutic agents and adjuvants for numerous diseases. It is to be hoped that CpG ODN treatment of animals could also provide a cost-effective alternative to antibiotics by increasing resistance to disease-causative pathogens.

Słowa kluczowe

PL

oligodeoksynukleotydy CpG; medycyna; weterynaria; zastosowanie; uklad odpornosciowy; immunomodulacja; odpowiedz immunologiczna; pierwotna odpowiedz immunologiczna; wtorna odpowiedz immunologiczna; odpornosc naturalna; odpornosc nabyta

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2010
• Tom: 66
• Numer: 04
• Opis fizyczny: s.242-245,bibliogr.

Twórcy

autor

Chrzastek K

• Uniwersytet Przyrodniczy we Wroclawiu, pl.Grunwaldzki 45, 50-366 Wroclaw

autor

Wieliczko A.

Bibliografia

• 1. Beutler B.: Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004, 430, 257-263.
• 2. Chu R., Targoni O., Krieg A., Lehmann P., Harding C.: CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 1997, 186, 1623-1631.
• 3. Cohen J.: The immunopathogenesis of sepsis. Nature 2002, 420, 885-691.
• 4. Colonna M., Facchetti F.: TREM-1 (triggering receptor expressed on myeloid cells): a new player in acute inflammatory responses. J. Infect. Dis. 2003, 187 Suppl 2, S397-401.
• 5. Elkins K., Rhinehart T., Stibitz S., Conover J., Klinman D.: Bacterial DNA protects mice against lethal infection by intracellular bacteria. J. Immunol. 1999, 162, 2991-2997.
• 6. Erb K., Wohlleben G.: Novel vaccines protecting against the development of allergic disorders: a double-edged sword? Curr. Opin. Immunol. 2002, 14, 633-643.
• 7. Hirai K., Sasaki H., Sakamoto H., Takeshita F., Asano K., Kubota Y., Ochiya T., Terada M.: Antisense oligodeoxynucleotide against HST-1/FGF-4 suppresses tumorigenicity of an orthotopic model for human germ cell tumor in nude mice. J. Gene Medicine 2003, 5, 951-957.
• 8. Inohara N., Ogura Y, Nuñez G.: Nods: a family of cytosolic proteins that regulate the host response to pathogens. Curr. Opin. Microbiol. 2002, 5, 76-80.
• 9. Jain V., Kitagaki K., Kline J.: CpG DNA and immunotherapy of allergic airway diseases. Clin. Exp. Allergy. 2003, 33, 1330-1335.
• 10. Jain V., Kline J.: CpG DNA: immunomodulation and remodelling of the asthmatic airway. Expert Opin. Biol. Ther. 2004, 4, 1533-1540.
• 11. Klinman D.: CpG motifs expressed by bacterial DNA rapidly induce lymphocyte to secrete IL-6, IL-12, and IFN-g. Proc. Natl Acad. Sci. USA 1996, 93, 2879-2883.
• 12. Klinman D.: Therapeutic applications of CpG-containing oligodeoxynucleotides. Antisense Nucl. Acid. Drug. Dev. 1998, 8, 181-1884.
• 13. Klinman D., Conover J., Coban C.: Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect. Immun. 1999, 67, 5658-5663.
• 14. Krieg A.: CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002, 20, 709-760.
• 15. Krieg A.: The role of CpG motifs in innate immunity. Curr. Opin. Immunol. 2000, 12, 35-43.
• 16. Krieg A., Yi A., Matson S., Waldschmidt T., Bishop G., Teasdale R., Koretzky G., Klinman D.: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374, 546-549.
• 17. Kubota S.: Ornithine decarboxylase and cancer. Cancer J. 1998, 11, 294-297.
• 18. Liu C., Xu Z., Gupta D., Dziarski R.: Peptidoglycan recognition proteins: a novel family of four human innate immunity pattern recognition molecules. J. Biol. Chem. 2001, 276, 34686-34694.
• 19. Mackinnon K., He H., Swaggerty C., McReynolds J., Genovese K., Duke S., Nerren J., Kogut M.: In ovo treatment with CpG oligodeoxynucleotides decreases colonization of Salmonella enteriditis in broiler chickens. Vet. Immunol. Immunopathol. 2009, 127, 371-375.
• 20. McCluskie M., Weeratna R.: Novel adjuvant systems. Curr. Drug Targets Infect. Disord. 2001, 1, 263-271.
• 21. Nakazawa K., Nemoto T., Hata T., Seyama Y., Nagahara S., Sano A., Itoh H., Nagai Y., Kubota S.: Single-injection ornithine decarboxylase- directed antisense therapy using atelocollagen to suppress human cancer growth. Cancer 2007, 109, 993-1002.
• 22. Patel B., Gomis S., Dar A., Willson P., Babiuk L., Potter A., Mutwiri G., Tikoo S.: Oligodeoxynucleotides containing CpG motifs (CpG-ODN) predominantly induce Th1-type immune response in neonatal chicks. Dev. Comp. Immunol. 2008, 32, 1041-1049.
• 23. Pegg A.: Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res. 1988, 48, 759-774.
• 24. Pegg A., Shantz L., Coleman C.: Ornithine decarboxylase as atarget for chemoprevention. J. Cell. Biochem. Suppl. 1995, 22, 132-138.
• 25. Sparwasser T., Koch E., Vabulas R., Heeg K., Lipford G., Ellwart J., Wagner H.: Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol. 1998, 28, 2045-2054.
• 26. Taghavi A., Allan B., Mutwiri G., Foldvari M., Van Kessel A., Willson P., Babiuk L., Potter A., Gomis S.: Enhancement of immunoprotective effect of CpG-ODN by formulation with polyphosphazenes against E. coli septicemia in neonatal chickens. Curr. Drug Deliv. 2009, 6, 76-82.
• 27. Taghavi A., Allan B., Mutwiri G., Van Kessel A., Willson P., Babiuk L., Potter A., Gomis S.: Protection of neonatal broiler chicks against Salmonella Typhimurium septicemia by DNA containing CpG motifs. Avian Dis. 2008, 52, 398-406.
• 28. Wang Y., Shan C., Ming S., Liu Y., Du Y., Jiang G.: Immunoadjuvant effects of bacterial genomic DNA and CpG oligodeoxynucleotides on avian influenza virus subtype H5N1 inactivated oil emulsion vaccine in chicken. Res. Vet. Sci. 2009, 86, 399-405.
• 29. Xie H., Raybourne R., Babu U., Lillehoj H., Heckert R.: CpG-induced immunomodulation and intracellular bacterial killing in a chicken macrophage cell line. Dev. Comp. Immunol. 2003, 27, 823-834.
• 30. Yamamoto S., Yamamoto T., Kataoka T., Kuramoto E., Yano O., Tokunaga T.: Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity. Immunol. 1992, 148, 4072-4076.
• 31. Zhang L., Zhang M., Li J., Cao T., Tian X., Zhou F.: Enhancement of mucosal immune responses by intranasal co-delivery of Newcastle disease vaccine plus CpG oligonucleotide in SPF chickens in vivo. Res. Vet. Sci. 2008, 85, 495-502.
• 32. Zimmermann S., Egeter O., Hausmann S., Lipford G., Röcken M., Wagner H., Heeg K.: CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J. Immunol. 1998, 160, 3627-3630.